Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Published:2023-10 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Kirby Joslyn S.,Okun Martin M.,Alavi Afsaneh,Bechara Falk G.,Zouboulis Christos C.,Brown Kurt,Santos Leandro L.,Wang Annie,Bibeau Kristen B.,Kimball Alexa B.,Porter Martina L.

Funder

Incyte

Publisher

Elsevier BV

Subject

Dermatology

Reference37 articles.

1. Insights into hidradenitis suppurativa;van Straalen;J Allergy Clin Immunol,2022

2. What causes hidradenitis suppurativa?-15 years after;Zouboulis;Exp Dermatol,2020

3. Profound consequences of hidradenitis suppurativa: a review;Matusiak;Br J Dermatol,2020

4. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis;Jfri;JAMA Dermatol,2021

5. Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes;Shao;J Am Acad Dermatol,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Januskinaseinhibitoren für dermatologische Erkrankungen;Die Dermatologie;2024-08-30

2. Up-and-Coming Drugs for the Treatment of Vitiligo;ANN DERMATOL;2024

3. Hidradenitis suppurativa;Die Dermatologie;2024-03-21

4. Polish guidelines for the diagnosis and treatment of hidradenitis suppurativa;Dermatology Review;2024

5. Up-and-Coming Drugs for the Treatment of Vitiligo;Annals of Dermatology;2024